The Latest Cardiac and Vascular News
Stellarex’s unique coating enables a low therapeutic drug dose and has demonstrated a significant treatment effect and high safety profile Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced two new balloons to its Stellarex 0.035” low-dose drug-coated balloon (DCB) portfolio. The new 200mm […]
Primary safety analysis of Stellarex drug-coated balloon (DCB) three-year data, comprising the largest published, pooled set of randomized controlled trial (RCT) data for a single paclitaxel-based device, shows no difference in mortality between patients treated with the Philips Stellarex DCB and those treated with percutaneous angioplasty, the current standard of […]
Stellarex is the only low-dose [1] drug-coated balloon (DCB) to demonstrate a significant treatment effect and high safety profile through 3 years ILLUMENATE Pivotal trial showcases durable primary patency (maintained blood flow) in the most complex patient pool studied in a DCB randomized clinical trial No significant difference in mortality […]
AMSTERDAM, Nov. 12, 2018 /PRNewswire/ — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced enrollment of the first U.S. patient in the Stellarex ILLUMENATE Below-the-Knee (BTK) Investigational Device Exemption (IDE) study, led by principal investigators Dr. Bill Gray and Dr. Mahmood K. Razavi. This unique global, prospective, randomized, multi-center trial is designed […]
